The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Using MRD to better understand treatment responses in patients with CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, summarizes the importance of using measurable residual disease (MRD) to better understand and classify patient responses to therapy in chronic lymphocytic leukemia (CLL), and further highlights how MRD can be used to improve patient outcomes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
